Akebia Therapeutics, Inc. (AKBA) Earnings Call Transcripts
Akebia Therapeutics, Inc.'s Latest Earnings Call - April 2, 2026
In the first quarter of fiscal year 2026, Akebia Therapeutics reported revenues of $227 million, primarily driven by its anemia treatment Vafseo, which management expects to grow into a $1 billion market this year. The company is transitioning from reliance on Auryxia, which faces generic competition, to Vafseo as its primary revenue driver. Management highlighted significant patient access growth for Vafseo, with prescribing access expanding from 40,000 to 290,000 patients, and improved adherence rates, which increased from 70-75% to 87%. No specific earnings per share (EPS) figures were provided, and there were no changes to guidance, though management expressed optimism about future growth prospects.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $227M (beat) |
| Patient Access for Vafseo | 290,000 patients (positive) |
| First-Fill Adherence Rate | 87% (positive) |
| Market Size for Vafseo | $1B (positive) |
| AKB-097 Phase II Trial Start | Second half of 2026 (positive) |
| AKB-9090 Phase I Trial Start | Upcoming (positive) |
Guidance from management
Management maintained its revenue guidance for Vafseo, anticipating it will grow into a $1 billion market in 2026. There were no specific changes to overall financial guidance provided during the call.
What management said
Thank you. We will now begin with a few questions on AKB-097. These questions come from the team at Jefferies. First, what is the most compelling evidence that tissue localized C3D targeting can deliver efficacy comparable to systemic complement inhibition without meaningful systemic immunosuppression?
The next question comes from the team at Leerink Partners and also [ Matt Caufield ] from HCW. I had a similar question. Praliciguat is entering a shifting regulatory landscape in FSGS, what level of UPCR reduction do you believe is clinically meaningful for Praliciguat to be competitive versus the current standard of care?
What analysts pressed on
Analysts expressed concerns regarding the competitive landscape for kidney disease treatments and the regulatory hurdles that Praliciguat may face. There were questions about the clinical efficacy of new therapies compared to existing standards of care, especially in light of the evolving treatment landscape.
Main topics on the call
- Patient Access Growth — Akebia has significantly expanded patient access for Vafseo, increasing from 40,000 to 290,000 patients. This growth is critical for driving future revenue as management aims to capture a larger share of the $1 billion a...
- Improved Adherence Rates — Management noted that first-fill adherence rates have improved from 70-75% to approximately 87% due to a shift to observed dosing. This increase is expected to enhance long-term revenue stability for Vafseo.
- Pipeline Development — Akebia is advancing multiple products in its pipeline, including Praliciguat for FSGS and AKB-097 for complement-mediated kidney diseases. Management emphasized the potential market opportunities, with Praliciguat target...
- Regulatory Landscape for Praliciguat — Management acknowledged the shifting regulatory landscape for FSGS treatments but expressed confidence in Praliciguat's mechanism of action. They believe it could provide a competitive edge in reducing proteinuria, a key...
Read the full Akebia Therapeutics, Inc. transcript (April 2, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc. (AKBA) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqCM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 42 calls on record spanning January 15, 2020 to August 5, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 42 Akebia Therapeutics, Inc. earnings call transcripts on record, spanning January 15, 2020 to August 5, 2026. Based on this history, Akebia Therapeutics, Inc. reports quarterly. The most recent call on file is dated August 5, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- AKBA
- Exchange
- NasdaqCM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 42
- First call
- January 15, 2020
- Most recent
- August 5, 2026
- Reporting cadence
- quarterly